Short Interest in Vapotherm Inc (NYSE:VAPO) Declines By 41.1%
Vapotherm Inc (NYSE:VAPO) was the target of a large drop in short interest in August. As of August 31st, there was short interest totalling 123,300 shares, a drop of 41.1% from the July 31st total of 209,500 shares. Approximately 1.2% of the company’s stock are short sold. Based on an average trading volume of 119,800 shares, the short-interest ratio is currently 1.0 days.
Separately, Zacks Investment Research upgraded Vapotherm from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Friday, August 2nd. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $23.67.
Shares of Vapotherm stock traded down $0.37 during trading on Friday, reaching $9.06. The company’s stock had a trading volume of 195,395 shares, compared to its average volume of 83,562. The company has a quick ratio of 4.34, a current ratio of 5.22 and a debt-to-equity ratio of 1.42. Vapotherm has a 12-month low of $8.30 and a 12-month high of $24.63. The company has a market capitalization of $157.85 million and a P/E ratio of -0.66. The business has a 50 day moving average price of $13.80 and a 200-day moving average price of $17.74.
In related news, insider John Landry bought 3,000 shares of the stock in a transaction on Thursday, September 5th. The shares were bought at an average cost of $10.34 per share, for a total transaction of $31,020.00. Following the purchase, the insider now owns 97,703 shares of the company’s stock, valued at approximately $1,010,249.02. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Joseph Army bought 15,000 shares of the stock in a transaction on Friday, August 2nd. The stock was bought at an average price of $14.28 per share, for a total transaction of $214,200.00. The disclosure for this purchase can be found here. Insiders have bought a total of 86,382 shares of company stock worth $1,165,307 in the last three months. Corporate insiders own 34.40% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Deutsche Bank AG purchased a new stake in Vapotherm during the fourth quarter valued at about $121,000. Marshall Wace North America L.P. purchased a new stake in shares of Vapotherm in the first quarter worth about $161,000. Charles Schwab Investment Management Inc. boosted its position in shares of Vapotherm by 10.2% in the second quarter. Charles Schwab Investment Management Inc. now owns 12,488 shares of the company’s stock worth $288,000 after buying an additional 1,151 shares during the period. Monashee Investment Management LLC purchased a new stake in shares of Vapotherm in the second quarter worth about $484,000. Finally, Arnhold LLC boosted its position in shares of Vapotherm by 123.9% in the first quarter. Arnhold LLC now owns 25,434 shares of the company’s stock worth $500,000 after buying an additional 14,075 shares during the period. 50.85% of the stock is owned by hedge funds and other institutional investors.
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Featured Story: Support Level
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.